PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Leuk Lymphoma. Author manuscript; available in PMC Apr 20, 2012.
Published in final edited form as:
PMCID: PMC3331678
NIHMSID: NIHMS365265
Association of HLA-DQB1 alleles with risk of follicular lymphoma
Nicholas K. Akers,1 John D. Curry,1 Lucia Conde,1 Paige M. Bracci,2 Martyn T. Smith,1 and Christine F. Skibola1
1Division of Environmental Health Sciences, School of Public Health, University of California, Berkeley, CA, USA
2Department of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco, San Francisco, CA, USA
Corresponding author: Nicholas Akers, kipp/at/berkeley.edu B84 Hildebrand Hall rm. 211, UC Berkeley, Berkeley, CA 94720, Phone: 510-642-8688, Fax: 510-642-0427
In a recent genome-wide association study of follicular lymphoma (FL), we identified novel risk alleles on chromosome 6p21.33 that appeared to be part of an extended haplotype including HLA-DRB1*0101, DQA1*0101, and DQB1*0501. To follow up on these findings, we obtained 2–4 digit HLA-DQB1 allelotypes on a subset of 265 FL cases and 757 controls using a novel assay that applies multiplexed ligation-dependent probe amplification (MLPA). We confirmed a positive association between FL and the HLA-DQB1*05 allele group (OR=1.70, 95% CI 1.28–2.27; adjusted p-value=0.013) and also identified an allele group inversely associated with FL risk, HLA-DQB1*06 (OR=0.51, 95% CI 0.38–0.69; adjusted p-value=4.46×10−5). Although these findings require verification, the role of HLA class II proteins in B-cell survival and proliferation make this a biologically plausible association.
Keywords: follicular lymphoma, MHC, HLA, DQ, NHL
Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma (NHL), comprising up to 30% of all NHL cases in populations worldwide1. Thus the more than 300,000 incident NHL cases diagnosed each year2, are comprised of approximately 24,000–90,000 incident cases of FL. Although FL has a relatively long median survival of 8–10 years, more than 20% of FL patients transform to an aggressive lymphoma with a poor clinical outcome3.
The “defining event” for FL is the t(14;18) chromosomal translocation. However this signature translocation also is present in greater than 50% of healthy individuals, and is not sufficient to cause the full transformation of a B-cell to a FL tumor4. Common gene variants appear to play a significant role in lymphomagenesis57. Candidate gene studies have indentified single nucleotide polymorphisms (SNPs) associated with FL susceptibility in pathways related to oxidative stress, energy regulation, detoxification, and immunoregulation7,8. In a recent genome-wide association study (GWAS) of 1,465 cases and 6,958 controls, we identified and validated highly significant associations between FL and non-coding SNPs in strong linkage disequilibrium (LD) (rs10484561 odds ratio (OR)=1.95, 95% confidence interval (CI)=1.72–2.22, trend p-value=1.12×10−29; rs7755224 OR=2.07 95%CI=1.76–2.42, trend p-value=2.00×10−19; D′=1.0, r2=0.99) in the human leukocyte antigen (HLA) region on chromosome 6p21.334. Using tag SNPs for HLA alleles9, we identified an extended haplotype containing the alleles HLA-DRB1*0101—HLA-DQA1*0101—HLA*DQB1*0501 that was in strong LD with rs108484561 and rs7755224 and associated with increased FL risk.
To confirm these findings, our group developed a novel assay to type the HLA-DQB1 locus using the multiplexed ligation-dependent probe amplification (MLPA) technique10. Allelotyping of 265 FL cases and 757 controls from a larger NHL case-control study based in the San Francisco Bay Area (2,050 cases and 2,081 controls)11 confirmed the high LD between rs10484561/rs7755224 and HLA-DQB1*05 alleles, and revealed a strong inverse association between FL and HLA-DQB1*06 alleles.
Study Population
A population-based case-control study of NHL (2055 cases, 2081 controls) was conducted in the San Francisco Bay Area that included incident cases diagnosed from 2001 through 2006. Details of the process and criteria for subject selection have been described elsewhere11. Briefly, eligible patients were aged 20–85 years and residents of one of the six Bay Area counties at the time of diagnosis. Controls were frequency matched to patients by age in five-year groups, sex and county of residence. Blood and/or buccal specimens were collected from eligible cases and controls that participated in the laboratory portion of the study (participation rates, 87% and 89%, respectively). Patient diagnostic pathology materials were re-reviewed by the study’s expert pathologist to confirm NHL diagnosis and histology. For this study, an HIV-negative subset of 265 FL cases and 757 controls restricted to white, non-Hispanics was selected for allelotyping. Of these, 203 FL cases (77%) and 160 controls (21%) were genotyped in our recent GWAS.
HLA-DQB1 Typing
Subjects were typed for HLA-DQB1 using a novel in-house designed assay based on the multiplexed ligation-dependent probe amplification (MLPA) methodology developed by MRC-Holland10 (www.mlpa.com). To verify the assay, 36 control DNAs were allelotyped using a DQB1 exon 2 sequencing-based typing technique adapted from van Dijk et al12 and sequences were compared to MLPA results. Agreement was 100% between both techniques.
Briefly, 50ng of genomic DNA from blood or buccal cells with a mix of probes to discern HLA-DQB1 alleles (see below) was incubated overnight at 60°C to allow the probes to anneal. The probes were designed such that two would meet directly at a key SNP site. A ligation step then used Taq DNA ligase (NEB, Ipswich, MA) to connect any probe pair that matched at the SNP site. Because each probe was designed at a known length and each probe had identical PCR-primer ends, ligated probes were amplified using PCR, and different sized PCR products were identified using capillary fragment analysis on an ABI 3730xl (UC Berkeley DNA Sequencing Facility).
The novel HLA-DQB1 typing method developed for this study (manuscript submitted) using our probes (for sequences see http://gel.berkeley.edu/pdf/238.pdf) was able to distinguish the following alleles: DQB1*02, DQB1*03, DQB1*04, DQB1*05, DQB1*0601, DQB1*0602, DQB1*0603, DQB1*0604, and DQB1*0609. The following allele combinations were indistinguishable by our MLPA method: (*0601/*0601) vs. (*0601/*0602); (*0603/*0603) vs. (*0602/*0603); (*0604/*0604) vs. (*0604/*0609); and (*0602/*0604) vs. (*0603/*0604) vs. (*0603/*0609). Sequencing-based typing12 was used to distinguish these cases.
Statistical Analysis of Allele Associations
For each HLA-DQB1 allele, a 3×2 contingency table was constructed that contained the number of subjects carrying zero, one, or two copies of the tested allele among the cases and controls. The number of subjects carrying one or two copies of an allele was compared to the number carrying zero copies of that allele (Presence/Absence—Table I). Then the number of subjects carrying two copies of an allele was compared to the number of subjects carrying zero copies of that allele (Homozygous—Table I). The fisher.test function from the stat package in R (http://stat.ethz.ch/R-manual/R-devel/library/stats/html/fisher.test.html) was used to estimate ORs and 95% CIs using conditional maximum likelihood estimation, and to determine the significance of the distribution of the alleles between cases and controls. The p-values for the allelotype tests were adjusted using the Bonferroni correction with the p.adjust function from the same package in R.
Table I
Table I
Odds ratios (OR) and 95% confidence intervals (CI) for two-digit HLA-DQB1 alleles associated with risk of follicular lymphoma (FL) from a population-based case-control study of non-Hodgkin lymphoma in the San Francisco Bay Area.
Haploview (http://www.broadinstitute.org/haploview/haploview) was used to determine LD between previously discovered SNPs and HLA-DQB1 alleles. Using sequence information from the IMGT/HLA database (http://www.ebi.ac.uk/imgt/hla/), genotype information was inferred for 32 SNPs in exons 2 and 3 of HLA-DQB1 based on our determined allelotypes. These SNPS can act as unique tags for specific alleles, or groups of alleles. The allele-based SNP genotypes were combined with the corresponding GWAS genotype data (203 cases, 160 controls),5 including rs10484561 and rs7755224. Haploview was used to analyze this combined data file and determine LD between rs10484561, rs7755224, and allele-specific SNPs of HLA-DQB1. We then reported those allele groups in HLA-DQB1 whose SNPs had the strongest LD with rs10484561/rs7755224.
The population two-digit HLA-DQB1 allele frequencies are presented in Table I. These two-digit alleles represent major groupings of DQB1 alleles, which were used to screen for associations. We observed a statistically significant increased risk of FL associated with the DQB1*05 allele group (OR=1.70, 95% CI 1.28–2.27; adjusted p-value=0.013). A strong association with reduced risk for FL also was found with the DQB1*06 allele group (OR=0.51, 95% CI 0.38–0.69; adjusted p-value=4.46×10−5).
Our assay allowed the separation of the *06 group into its component alleles, thus we were able to determine the alleles within the *06 group that contributed to the observed inverse association (Table II). Of the 5 major alleles that comprise the *06 group in Caucasians, *0602, *0603, *0604, and *0609, all were associated with reduced FL risk, whereas the *0601 allele was associated with increased FL risk (OR=2.04, 95%CI=0.72–5.44). However, for *0601, statistical power was limited due to the low frequency of this allele. There was a decreasing trend in ORs associated with each *06 allele carried (1 allele: OR=0.51, 95% CI 0.38–0.69, 2 alleles: OR=0.16, 95% CI=0.04–0.45, Table I). For the *05 risk allele, one allele was associated with a 1.7-fold increased risk of FL (OR=1.70, 95% CI=1.28–2.27) and two alleles with a 2-fold increased risk (OR=2.04, 95%CI=1.00–4.00; Table I).
Table II
Table II
ORs and 95% CIs for four-digit alleleotypes within the HLA-DQB1*06 group associated with risk of follicular lymphoma (FL) from a population-based case-control study of non-Hodgkin lymphoma in the San Francisco Bay Area.
Measures of LD (Haploview v4.1) were used to verify that our disease-associated alleles were the same genetic signal that was reported previously. In Table III, our findings showed that the risk alleles, rs10484561 and rs7755224, identified in our GWAS13 were in strongest LD with SNPs found only in the HLA-DQB1*05 allele (r2=0.71). LD also was examined between allele-specific SNPs and SNPs near HLA-DQB1 including rs9274614, that was inversely related to FL susceptibility (OR=0.57 95%CI=0.40–0.80, trend p-value=7.04×10−4) in our earlier study5. This SNP showed strong LD with the *0602, *0603, *0604, and *0609 groups (r2=0.94), suggesting that the observed signal for rs9274614 could be driven by HLA-DQB1*06 alleles.
Table III
Table III
Linkage disequilibrium (LD) valuesa between previously published data4 and alleles of HLA-DQB1 using overlapping data from 203 FL cases and 160 controls.
Here, we present evidence of positive and negative associations between HLA-DQB1*05 and *06 alleles and risk of FL, respectively. These results confirm our previous findings of an association between FL risk and SNPs in the HLA-DRB1*0101—HLA-DQA1*0101—HLA-DQB1*0501 extended haplotype. A recent study reported that HLA-DRB1*0101 was associated with increased risk for FL, whereas HLA-DRB1*13 was inversely associated with FL risk14. These alleles are in strong LD with HLA-DQB1*0501 and HLA-DQB1*06, respectively. Thus, our results highlight the need for further studies to determine whether HLA-DQB1 alleles, HLA-DRB1 alleles, or some other gene variant(s), are causal in the pathogenesis of FL. Due to extended LD in the HLA region, a typing study of non-Europeans with different LD patterns will aid in differentiating disease association signals in HLA-DRB1 from those in HLA-DQB1.
HLA alleles associated with disease risk may alter the presentation of specific antigens of autoimmune or infectious origin, and thereby influence the immune response. For example, with type-1 diabetes the significant association between HLA class II alleles and disease risk15 is attributed to differential presentation of insulin by specific HLA class II protein isoforms16,17. This, in turn, effects T-cell mediated destruction of insulin-secreting pancreatic β-cells. Similar models have been proposed to explain associations of HLA alleles with narcolepsy, celiac disease, and rheumatoid arthritis17. Although it is possible that FL pathogenesis is initiated by a similar mechanism dependent on a single antigen, a more generalized mechanism may be at play. Comparisons of the strength of associations between risk alleles and disease implicate a unique causal pathway for FL. In the cases of narcolepsy, celiac disease, and rheumatoid arthritis, >90% of patients are carriers of a risk allele17. In contrast, 43% of FL cases in this study carried an HLA-DQB1*05 allele. This implies a more subtle increase in risk per allele, or perhaps heterogeneity in the causal pathways in FL patients.
Changes in specific amino acids in HLA proteins are one reason that different immune systems may respond differently to the same antigen. Polymorphisms in the polypeptide binding groove can affect preference of the polypeptides to be presented to T-cells18 and thereby influence the immune response. For example, if we compare HLA-DQB1*0501 and HLA-DQB1*0602 (http://www.ebi.ac.uk/imgt/hla/), seven amino acid changes are in pockets known to influence antigen binding or interaction with the T-cell receptor1719. If these amino acid changes affect the immune response to an antigen, it could conceivably influence susceptibility to FL via several mechanisms such as chronic immune activation, T-cell receptor stimulation or effects on HLA gene expression on antigen presenting cells.
Chronic immune activation is one proposed mechanism of lymphomagenesis that may explain the association of HLA class II alleles with FL risk. B-cell proliferation is dependent on two signals, the first resulting from B-cell receptor interactions with antigen, and the second resulting from HLA class II-bound antigen-peptide interactions with T-cells20. This two-part signal leads to clonal proliferation, class switch recombination and somatic hypermutation of B-cells. Chronic immune activation ensues when an autoantigen or a chronic infectious agent repeatedly provides growth signals to B-cells. Because class switch recombination and somatic hypermutation have been associated with DNA strand breaks, this process is potentially oncogenic and has been proposed as a mechanism of B-cell lymphomagenesis21. The extent that a given antigen will cause chronic B-cell stimulation may be modified by the polymorphisms which define HLA class II alleles.
Interactions with regulatory T-cells (Tregs) represent a second mechanism in which a differentially presented antigen could affect FL risk. B-cell NHL tumors contain high levels of Tregs compared to control tissues, and these Tregs suppress proliferation of tumor fighting CD4+ and CD8+ T-cells22,23. Recent evidence indicates that T-helper cells can be converted to Tregs by malignant FL B-cells in a process involving T-cell receptor stimulation24. Because HLA class II molecules interact with the T-cell receptor, this suggests a role for HLA alleles in the generation of Tregs. If an antigen, unique to FL, were differentially presented by the HLA class II alleles, it could possibly affect Tregs levels, thus modifying FL risk. The anti-apoptotic protein, BCL-2, which is up-regulated in FL due to the t(14:18) translocation, may be a plausible candidate antigen that is unique for FL. Further studies will be needed to determine the potential role of Tregs as a possible causal intermediate between HLA class II alleles and FL risk.
FL immune evasion may also be caused by decreased HLA class II protein expression. Decreased HLA class II protein expression has been linked to poor survival in DLBCL patients, likely the result of decreased immune surveillance25. Additional research will be needed to assess the role of survival and HLA class II expression in FL, and the role that HLA allelotypes play on expression of HLA class II proteins.
In summary, this paper provides further evidence that HLA-DQB1*05 is associated with FL risk, and demonstrates a novel inverse association between HLA-DQB1*06 alleles and FL risk. Currently, it is unclear whether these HLA-DQB1 alleles are causal or merely markers of association. Here, we propose several mechanisms to support the biological plausibility of an association between HLA class II alleles with FL risk. Further genetic studies will be needed that include a large number of participants to provide in-depth coverage of the entire HLA class II region to elucidate the role of HLA alleles in the pathogenesis of FL.
Acknowledgments
This work was supported by grants CA122663, CA104682, CA87014 and CA89745 from the National Cancer Institute, National Institutes of Health.
Footnotes
DECLARATION OF INTERESTS
The authors have no conflicts of interest to declare.
1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin’s lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project. Ann Oncol. 1998;9:717–720. [PubMed]
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74–108. [PubMed]
3. Montoto S, Davies AJ, Matthews J, et al. Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol. 2007;25:2426–2433. [PubMed]
4. Staudt LM. A closer look at follicular lymphoma. N Engl J Med. 2007;356:741–742. [PubMed]
5. Conde L, Halperin E, Akers NK, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010;42:661–664. [PMC free article] [PubMed]
6. Skibola CF, Bracci PM, Halperin E, et al. Genetic variants at 6p21.33 are associated with susceptibility to follicular lymphoma. Nat Genet. 2009;41:873–875. [PMC free article] [PubMed]
7. Skibola CF, Curry JD, Nieters A. Genetic susceptibility to lymphoma. Haematologica. 2007;92:960–969. [PMC free article] [PubMed]
8. Nieters A, Bracci PM, de Sanjose S, et al. A functional TNFRSF5 polymorphism and risk of non-Hodgkin lymphoma, a pooled analysis. Int J Cancer. 2010 [PubMed]
9. de Bakker PI, McVean G, Sabeti PC, et al. A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC. Nat Genet. 2006;38:1166–1172. [PMC free article] [PubMed]
10. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 2002;30:e57. [PMC free article] [PubMed]
11. Skibola CF, Bracci PM, Halperin E, et al. Polymorphisms in the estrogen receptor 1 and vitamin C and matrix metalloproteinase gene families are associated with susceptibility to lymphoma. PLoS One. 2008;3:e2816. [PMC free article] [PubMed]
12. van Dijk A, Melchers R, Tilanus M, Rozemuller E. HLA-DQB1 sequencing-based typing updated. Tissue Antigens. 2007;69 (Suppl 1):64–65. [PubMed]
13. Conde L, Halperin E, Akers NK, et al. Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet. 2010;42:661–664. [PMC free article] [PubMed]
14. Wang SS, Abdou AM, Morton LM, et al. Human leukocyte antigen class I and II alleles in non-Hodgkin lymphoma etiology. Blood. 2010 [PubMed]
15. She JX. Susceptibility to type I diabetes: HLA-DQ and DR revisited. Immunol Today. 1996;17:323–329. [PubMed]
16. Caillat-Zucman S. Molecular mechanisms of HLA association with autoimmune diseases. Tissue Antigens. 2009;73:1–8. [PubMed]
17. Jones EY, Fugger L, Strominger JL, Siebold C. MHC class II proteins and disease: a structural perspective. Nat Rev Immunol. 2006;6:271–282. [PubMed]
18. Marsh SG, Parham Peter, Barber Linda D. The HLA FactsBook. San Diego: Academic Press; 2000.
19. Siebold C, Hansen BE, Wyer JR, et al. Crystal structure of HLA-DQ0602 that protects against type 1 diabetes and confers strong susceptibility to narcolepsy. Proc Natl Acad Sci U S A. 2004;101:1999–2004. [PubMed]
20. Kindt TJ, Goldsby Richard A, Osborne Barbara A. Kuby Immunology. 6. New York: W.H. Freeman and Company; 2007.
21. Kuppers R. Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005;5:251–262. [PubMed]
22. Yang ZZ, Novak AJ, Stenson MJ, Witzig TE, Ansell SM. Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood. 2006;107:3639–3646. [PubMed]
23. Hilchey SP, De A, Rimsza LM, Bankert RB, Bernstein SH. Follicular lymphoma intratumoral CD4+CD25+GITR+ regulatory T cells potently suppress CD3/CD28-costimulated autologous and allogeneic CD8+CD25− and CD4+CD25− T cells. J Immunol. 2007;178:4051–4061. [PubMed]
24. Ai WZ, Hou JZ, Zeiser R, Czerwinski D, Negrin RS, Levy R. Follicular lymphoma B cells induce the conversion of conventional CD4+ T cells to T-regulatory cells. Int J Cancer. 2009;124:239–244. [PMC free article] [PubMed]
25. Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project. Blood. 2004;103:4251–4258. [PubMed]